If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
106.50    0.50 (0.47%)
Bid:
104.00
Ask:
109.00
Spread: 5.00 (4.808%)
Market Cap: £64.07m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Positive Trading Update

7 Sep 2010 07:00

RNS Number : 2445S
Intercede Group PLC
07 September 2010
 



7 September 2010

Intercede Group plc

("Intercede")

 

Positive Trading Update

 

Intercede announces strong levels of business throughout the summer period.

The Healthcare sector has made a significant contribution to revenue and in July orders from an existing UK customer generated more than £800,000 in cash receipts. 

US government customers have continued to buy additional software licenses and a further US Federal Agency has purchased the Intercede MyID system. This brings the total number of Agencies using Intercede MyID for HSPD-12/PIV compliance to 13. Lockheed Martin and FAA continue to buy materially significant quantities of professional service time from Intercede in support of their large enterprise-wide identity programs.

Internationally, Intercede has added the Australian government and a South African bank to its customer list. Additional revenues are accruing for the next phase of the Kuwait national ID program and an existing customer that has purchased Intercede MyID to power a Switzerland-wide electronic identity service.

Intercede's sales activities continue to increase the pipeline of future business. A number of contract awards are also pending imminent closure, and the company is on target to meet full year expectations. Intercede remains in a strong cash position at the end of August.

Richard Parris, Chairman and Chief Executive of Intercede, said:

"Our level of business activity is at an all time high driven by repeat orders against existing contracts, new orders from new customers and a growing pipeline of high value prospects. Although, as expected, we have seen a reduction in UK Government orders compared to the same period last year, this is being compensated for by international orders, particularly from the US."

About Intercede

Intercede is the producer of the MyID Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organisations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include more than 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

For more information visit http://www.intercede.com

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7600 1658

Clive Carver

Sarah Wharry

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

Francesca Tuckett

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKKADDFBKDKCK
Date   Source Headline
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity
18th Jul 20177:00 amRNSDirector/PDMR Shareholding & TVR
13th Jun 20177:00 amRNSCollaborations with VMWare and Imagination
7th Jun 201712:06 pmRNSHolding(s) in Company
7th Jun 201712:01 pmRNSHolding(s) in Company
7th Jun 20177:00 amRNSFinal Results
6th Jun 20177:00 amRNSLaunch of MyIDaaS
25th May 20177:00 amRNSSchedule 2(g) Disclosure
23rd May 20177:00 amRNSAppointment of Chief Sales Officer
17th May 20177:00 amRNSNon-Executive Director Appointment
9th May 20177:00 amRNSContract Win
8th May 20173:45 pmRNSShare Incentive Plan
8th May 20177:00 amRNSIntercede announces Secure Login for WordPress
5th Apr 20177:00 amRNSTrading Update
31st Mar 20177:00 amRNSListing of Convertible Loan Notes
20th Mar 20177:00 amRNSAppointment of VP, US Gov't & Enterprise Sales
15th Mar 20173:03 pmRNSShare Incentive Plan
9th Mar 20177:00 amRNSAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.